TY - JOUR A1 - Glutsch, Valerie A1 - Schummer, Patrick A1 - Kneitz, Hermann A1 - Gesierich, Anja A1 - Goebeler, Matthias A1 - Klein, Detlef A1 - Posch, Christian A1 - Gebhardt, Christoffer A1 - Haferkamp, Sebastian A1 - Zimmer, Lisa A1 - Becker, Jürgen C A1 - Leiter, Ulrike A1 - Weichenthal, Michael A1 - Schadendorf, Dirk A1 - Ugurel, Selma A1 - Schilling, Bastian T1 - Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG JF - Journal for ImmunoTherapy of Cancer N2 - Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) inhibition of up to 62%. However, primary and secondary resistance to PD-1/PD-L1 inhibition remains a so far unsolved clinical challenge since effective and safe treatment options for these patients are lacking.Fourteen patients with advanced (non-resectable stage III or stage IV, Union international contre le cancer 2017) Merkel cell carcinoma with primary resistance to the PD-L1 inhibitor avelumab receiving subsequent therapy (second or later line) with ipilimumab plus nivolumab (IPI/NIVO) were identified in the prospective multicenter skin cancer registry ADOREG. Five of these 14 patients were reported previously and were included in this analysis with additional follow-up. Overall response rate, progression-free survival (PFS), overall survival (OS) and adverse events were analyzed.All 14 patients received avelumab as first-line treatment. Thereof, 12 patients had shown primary resistance with progressive disease in the first tumor assessment, while two patients had initially experienced a short-lived stabilization (stable disease). Six patients had at least one systemic treatment in between avelumab and IPI/NIVO. In total, 7 patients responded to IPI/NIVO (overall response rate 50%), and response was ongoing in 4 responders at last follow-up. After a median follow-up of 18.85 months, median PFS was 5.07 months (95% CI 2.43—not available (NA)), and median OS was not reached. PFS rates at 12 months and 24 months were 42.9% and 26.8 %, respectively. The OS rate at 36 months was 64.3%. Only 3 (21%) patients did not receive all 4 cycles of IPI/NIVO due to immune-related adverse events.In this multicenter evaluation, we observed high response rates, a durable benefit and promising OS rates after treatment with later-line combined IPI/NIVO. In conclusion, our patient cohort supports our prior findings with an encouraging activity of second-line or later-line IPI/NIVO in patients with anti-PD-L1-refractory Merkel cell carcinoma. KW - Skin Neoplasms KW - CTLA-4 Antigen KW - Programmed Cell Death 1 Receptor KW - B7-H1 Antigen KW - Drug Therapy, Combination Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304613 SN - 2051-1426 VL - 10 IS - 11 ER - TY - JOUR A1 - Gilbert, Fabian A1 - Klein, Detlef A1 - Weng, Andreas Max A1 - Köstler, Herbert A1 - Schmitz, Benedikt A1 - Schmalzl, Jonas A1 - Böhm, Dirk T1 - Supraspinatus muscle elasticity measured with real time shear wave ultrasound elastography correlates with MRI spectroscopic measured amount of fatty degeneration JF - BMC Muscoskeletal Disorders N2 - Background: Fatty Degeneration (FD) of the rotator cuff muscles influences functional and anatomical outcome after rotator cuff repair. The MRI based estimation of fatty degeneration is the gold standard. There is some evidence that Ultrasound elastography (EUS) can detect local differences of tissue stiffness in muscles and tendons. Shear-wave elastography (SWE) was evaluated to determine the extent to which shear wave velocity was associated with measures of fatty degeneration. MRI-spectroscopic fat measurement was used as a reference to quantify the amount of fat in the muscle belly. Methods: Forty-two patients underwent SWE of the supraspinatus muscles at its thickest diameter. After ultrasound evaluation an MRI-spectroscopic fat measurement of the supraspinatus muscle was performed using the SPLASH-technique. A gel filled capsule was used to locate the measured area in the MRI. The values of shear wave velocity (SWV) measured with SWE and spectroscopic fat measurement were correlated statistically using Pearson’s correlation test. Results: Correlation of the fat amount measured with MRI-spectroscopy and the SWV measured with SWE was ρ =0.82. Spectroscopic measured fat ratio of the supraspinatus muscle ranged from 0% to 77.41% and SWV from 1.59 m/s to 5.32 m/s. In 4 patients no sufficient SWE could be performed, these individuals showed a larger diameter of the overlying soft tissue. SWV measured with SWE showed a good correlation with MRI spectroscopic fat amount of the supraspinatus muscle. Conclusion: These preliminary data suggest that SWE may be a sufficient tool in detecting and estimating the amount of fatty degeneration in the supraspinatus muscle in real time. Large overlying soft tissue may be a limitation in performing sufficient EUS. KW - shoulder surgery KW - rotator cuff KW - MRI KW - ultrasound KW - fatty degeneration Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-159378 VL - 18 IS - 549 ER - TY - JOUR A1 - Sauer, Stephanie A1 - Goltz, Jan P. A1 - Gassenmaier, Tobias A1 - Kunz, Andreas S. A1 - Bley, Thorsten A. A1 - Klein, Detlef A1 - Petritsch, Bernhard T1 - Partial Segmental Thrombosis of the Corpus Cavernosum (PSTCC) diagnosed by contrast-enhanced ultrasound: a case report JF - BMC Urology N2 - Background Partial segmental thrombosis of the corpus cavernosum (PSTCC) is a rare disease predominantly occurring in young men. Cardinal symptoms are pain and perineal swelling. Although several risk factors are described in the literature, the exact etiology of penile thrombosis remains unclear in most cases. MRI or ultrasound (US) is usually used for diagnosing this condition. Case presentation We report a case of penile thrombosis after left-sided varicocele ligature in a young patient. The diagnosis was established using contrast-enhanced ultrasound (CEUS) and was confirmed by contrast-enhanced magnetic resonance imaging (ceMRI). Successful conservative treatment consisted of systemic anticoagulation using low molecular weight heparin and acetylsalicylic acid. Conclusion PSTCC is a rare condition in young men and appears with massive pain and perineal swelling. In case of suspected PSTCC utilization of CEUS may be of diagnostic benefit. KW - MRI KW - priapism KW - corpus cavernosum KW - penile thrombosis KW - contrast-enhanced ultrasound Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126495 VL - 14 IS - 100 ER - TY - THES A1 - Klein, Detlef T1 - Dynamische kontrastmittelunterstützte Ultraschalluntersuchung fokaler Leberraumforderungen T1 - Quantitative Dynamic Contrast-enhanced Sonography of Hepatic Tumors N2 - Ziel: Versuch der Definition von Lebertumoren mit quantitativem dynamischem kontrast-verstärktem Ultraschall anhand der Beurteilung der Vaskularisation, wash-in, wash-out über einen definierten Zeitraum. Korrelation mit histologischen Befunden. Patienten und Methode: 42 Leberläsionen in 39 Patienten wurden mittels „Contrast Harmonic Imaging“ (CHI) über einen Zeitraum von 2 min nach einer Bolusinjektion von 10 ml Levovist® (300mg/ml, Schering AG, Berlin) untersucht. Die Untersuchungen wurden an einem Sonoline Elegra® (Siemens AG, Erlangen) mit einem frequenzvariablen 3,5 MHz Schallkopf durchgeführt. Das Kontrastmittelverhalten der Leberläsionen wurde durch eine speziell für Ultraschallkontrastmittel entwickelte Software (Axius™ ACQ (Siemens, Issaquah, WA)) quantifiziert. Repräsentative ROI wurden in das Zentrum der Läsion, über die gesamte Läsion, in normales Leberparenchym, sowie in repräsentative Lebergefäße (Leberarterie, Lebervene, Portalvene) gelegt. Die Kontrastmittelaufnahme der Leberläsionen wurde unterteilt in arteriell, portal-venös oder venös. Des Weiteren erfolgte eine Unterteilung in hypovaskular, isovaskular und hypervaskular im Vergleich zum normalen Leberparenchym. Zusätzlich wurde das Kontrastmittelverhalten innerhalb der Läsion beurteilt und unterteilt in zentrifugal, zentripetal, peripher und komplett. Alle Leberläsionen wurden vor und nach Kontrastmittelgabe von vier im Ultraschall, CT und MRT erfahrenen Radiologen ausgewertet ohne Kenntnis der Patientendaten oder des histologischen Ergebnis. Das Diagnosekriterium maligne wurde mittels einer ROC-Analyse ausgewertet. Zusätzlich wurden die durchschnittliche Sensitivität, Spezifität, sowie der positive und negative Vorhersagewert berechnet. Ergebnisse: Von 36 Raumforderungen lagen histologische Befunde vor. Histologisch ergaben sich 29 maligne Läsionen (HCC, n=11; CCC n=1; Lymphom, n=1, Metastasen, n=16) und 7 benigne Läsionen (Hämangiom, n=1; FNH, n=4, Adenom n=2). 4 FNH´s und 1 Hämangiom waren durch NUK, MRT und durch Langzeitkontrollen bestätigt. Die Auswertung der ROC-Analyse in Bezug auf das Kriterium maligne schwankte vor Kontrastmittelgabe zwischen 0,43 und 0,62 (Durchschnitt 0,57) und nach Kontrastmittelgabe zwischen 0,7 und 0,8 (Durchschnitt 0,75). Die durchschnittlichen Werte für die Sensitivität, Spezifität, negativer und positiver Vorhersagewert betrugen vor Kontrastmittelgabe 66%, 26%, 45% und 73% nach Kontrastmittelgabe 83%, 49%, 65% und 82%. Diskussion: Die Quantifizierung der verstärkten Gefäßdarstellung in Lebertumoren nach Bolus-Applikation eines Ultraschallkontrastmittels verbessert die Zuordnung zu einem malignen Prozess im Vergleich zum nativen Ultraschall. Um zuverlässigere Diagnosen stellen zu können ist eine Verbesserung der Auswertesoftware sowie die Berücksichtigung der neuen Generation von Ultraschallkontrastmitteln notwendig. N2 - OBJECTIVE. To define liver tumors using quantitative dynamic contrast-enhanced ultrasound compared to histological diagnosis, respectively long term follow ups. SUBJECTS AND METHODS. 42 focal liver lesions in 39 patients were examined by contrast harmonic imaging over a period of 2 min after bolus injection of 10 ml galactose-based contrast agent. Vascular enhancement was quantified by using a dedicated software that allowed to place representative regions of interest (ROI) in the centre of the lesion, in the complete lesions, in regular liver parenchyma, and in representative liver vessels (artery, vein, portal vein). Peak enhancement was judged to be either in the arterial, portal venous or in the late phase of liver perfusion. The lesion was described as hypovascular, isovascular and hypervascular compared to liver parenchyma. Contrast uptake was described as centrifugal or centripetal and peripheral or homogenous, respectively. Characterization of the lesions was performed unenhanced and after contrast by four independent specialists unaware of histology. Diagnosis of malignancy was evaluated by using a Receiver Operating Characteristic (ROC) analysis, also overall accuracy, average sensitivity, specificity, negative and positive predictive values were calculated. Interobserver agreement was defined by the Kappa statistics. RESULTS. Histologic examination revealed 29 malignant (hepatocellular carcinoma (HCC), n=11; cholangiocellular carcinoma (CCC), n=1; lymphoma, n=1; metastases, n=16), and 7 benign (hemangioma, n=1; focal nodular hyperplasia (FNH), n=4, adenoma, n=2) lesions. 6 benign lesions (hemangioma n=1; FNH n=5) were proved by long term follow up. ROC-Analysis regarding the diagnosis of malignancy showed values from 0.43 to 0.62 (mean 0.57) before and from 0.70 to 0.80 (mean 0.75) after contrast agent, respectively. The average values for sensitivity, specificity, accuracy, negative and positive predictive values were 66%, 26%, 62%, 45%, and 73% unenhanced and 83%, 49%, 73%, 65%, and 82% after contrast, respectively. The interobserver agreement was 0.54 and 0.65 for unenhanced and enhanced examinations, respectively. CONCLUSION. Quantitative dynamic contrast-enhanced sonography improves the diagnosis of malignancy in liver lesions. KW - Ultraschall KW - Levovist KW - Lebertumoren KW - Definition KW - Ultrasound KW - liver KW - US KW - contrast agents KW - Computer-aided diagnosis Y1 - 2004 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-15078 ER -